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ABSTRACT
Introduction: Previous research shows that patients
with an implanted cardioverter defibrillator (ICD) have a
fourfold increased mortality risk when suffering from
anxiety compared with ICD patients without anxiety.
This research supports the screening of ICD patients
for anxiety with the purpose of starting relevant
intervention.
Methods and analysis: Screen-ICD consists of 3
parts: (1) screening of all hospitalised and outpatient
patients at two university hospitals using the Hospital
Anxiety and Depression Scale (HADS), scores ≥8 are
invited to participate. (2) Assessment of type of anxiety
by Structured Clinical Interview for DSM Disorders
(SCID). (3) Investigator-initiated randomised clinical
superiority trial with blinded outcome assessment, with
1:1 randomisation to cognitive–behavioural therapy
(CBT) performed by a cardiac nurse with CBT training,
plus usual care or usual care alone. The primary
outcome is HADS-A measured at 16 weeks. Secondary
outcomes include Becks Anxiety Inventory, HeartQoL,
Hamilton Anxiety Scale, heart rate variability, ICD
shock, time to first shock and antitachycardia pacing.
A total of 88 participants will be included. The primary
analyses are based on the intention-to-treat principle
and we use a mixed model with repeated
measurements for continuous outcomes. For binary
outcomes (HADS-A score <8), we use a generalised
mixed model with repeated measurements.
Ethics and dissemination: The trial is performed in
accordance with the Declaration of Helsinki. All patients
must give informed consent prior to participation and
the trial is initiated after approval by the Danish Data
Protection Agency (RH-2015-282) and the regional
ethics committee (H-16018868). Positive, neutral and
negative results of the trial will be published.
Trial registration number: NCT02713360.
INTRODUCTION
Background and rationale
Patients with an implanted cardioverter
deﬁbrillator (ICD) have a fourfold increased
mortality risk when suffering from anxiety
compared with ICD patients without anxiety,
adjusted for age, sex, marital status and
comorbidity. This was established in our
research from 20141 and has led us to recom-
mend anxiety screening of ICD patients2
with the purpose of starting relevant therapy.
About 20–25% of all ICD patients experi-
ence anxiety.3 The burden does not seem to
be different depending on indication.4 Data
from the Danish Health and Medicines
Authority show that anxiety is the one condi-
tion that causes the highest amount of lost
work hours and costs Danish society around
8.6 billion DKK in lost earnings.5
Europe has an average ICD implantation
rate of 140 per million inhabitants and in
2013, a total of 1180 ﬁrst-time ICDs were
implanted in Denmark, equalling 214 per
million per year. In total, ∼8000 citizens in
Denmark live with an ICD.6
Strengths and limitations of this study
▪ This is the first study to screen for anxiety and
diagnose the type of anxiety in implanted cardio-
verter defibrillator (ICD) patients based on the
DSM-IV criteria and test a cognitive–behavioural
therapy (CBT) intervention aimed at that specific
type of anxiety.
▪ The interventional personnel include cardiac
nurses with a CBT education, making this inter-
vention easy to implement if positive outcomes
are found.
▪ Knowledge from this research is strongly needed
as many patients with ICD suffer from anxiety,
which is associated with mortality and morbidity.
▪ The trial is limited by possible non-responders.
The screening for anxiety is self-reported and
some patients need to mail the screening test
back by mail.
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There are physiological and behavioural processes that
lead to inappropriate cardiac outcomes due to anxiety.
Suggested models of the relationship between psych-
ology and heart disease highlight the role of the auto-
nomic nervous system. Psychological factors stimulate
the autonomic nervous system, which triggers produc-
tion of catecholamines, increases blood pressure,
decreases plasma volume, constricts coronary arteries
and increases cardiac demand, platelet activity, coagula-
tion and inﬂammation. Consequently, patients suffer
increased thrombogenesis, arrhythmogenesis, reduced
heart rate variability, increased myocardial oxygen
demand, myocardial ischaemia and impaired ventricular
function.7 Moser and Jong have summarised the behav-
ioural mechanisms that are another link between
anxiety and cardiac disease. Individuals with high
anxiety (compared with non-anxious individuals) have
more unhealthy food intake,8–10 smoke more,8–11
consume more drugs or alcohol,8 10 are less compliant
to treatment,12 sleep poorly8 10 and are less physically
active.8–10 All these elements are risk factors associated
with progression of cardiac disease.13
A review from 2014 concludes that interventions
with cognitive–behavioural therapy (CBT) can reduce
anxiety in ICD patients.14 A total of 11 studies investi-
gated the effect of CBT in ICD patients over a period of
13 years. There were two randomised controlled trials
(RCTs),15 16 one prospective observational study,17 one
cross-sectional study,18 four case–control studies19–22
and three case studies.23–25 These studies suffer from
methodological limitations, which is why conclusive evi-
dence does not exist. However, the two RCTs both ﬁnd
a signiﬁcant difference in anxiety over time in the CBT
group compared with the control group.15 19 In both
trials, the inclusion did not distinguish between
patients with and without anxiety and no screening was
performed. In a paper from 2015, screening was per-
formed in 690 ICD patients. Moderate to severe anxiety
was found in 70 patients and 29 were randomised in a
pilot CBT versus usual care trial. Signiﬁcant differences
were found after three CBT sessions.26 All interventional
trials were small and the intervention was very short.
No trial has tested a set-up with screening, identiﬁcation
of type of anxiety using Diagnostic and Statistical
Manual of Mental Disorders (DSM)27 criteria and a
longer lasting intervention, based on current
recommendations.28
Objectives
The aim of Screen-ICD is to (1) screen for anxiety, (2)
determine the type of anxiety in ICD patients and (3)
investigate the effect of a CBT intervention plus usual
care compared with usual care alone.
The hypothesis is that there will be a signiﬁcant differ-
ence in anxiety scores between intervention and usual
care groups after intervention, in favour of the interven-
tion group.
METHODS
Trial design
Screen-ICD is an investigator-initiated randomised clin-
ical superiority trial with blinded outcome assessment,
with 1:1 randomisation to CBT plus usual care or usual
care alone.
Study setting
Inclusion from two Danish urban university hospital
sites.
Eligibility criteria
Patients eligible for the trial must comply with all of the
following at randomisation: score 8 or more in the
Hospital Anxiety and Depression Scale—Anxiety
(HADS-A), score under 11 on the Hospital Anxiety and
Depression Scale—Depression (HADS-D) (unless the
HADS-A score exceeds the HADS-D score, anxiety must
be the primary problem), be over 18 years of age, have
had ICD implantation at any time but at least for
8 weeks, speak and understand Danish and give written
informed consent. The Consort ﬂow chart is presented
in ﬁgure 1.
Experimental intervention
The CBT intervention will aim at supporting patients to
cope with their heart disease and the limitations and
possibilities it brings to life. It will also focus on lifestyle
habits. CBT will be targeted on the speciﬁc type of
anxiety based on the DSM criteria. The therapy will
focus on the patient’s thoughts and feelings and the
actions that come with it, or the fundamental assump-
tions that cause these thoughts.
The methods of the therapeutic procedure are based
on learning theories and the fundament of cognitive
therapy was established by the psychiatrist Aron T. Beck
in the 1960s.29 For each type of anxiety (panic disorder,
agoraphobia, social phobia, speciﬁc phobia, obsessive
phobia, post-traumatic stress, generalised anxiety, anxiety
due to a general medical condition, anxiety disorder not
otherwise speciﬁed), a speciﬁc protocol will be followed
based on CBT. The treatment of anxiety in ICD patients
will contain some overall components:
1. Analysis of the problem: The patient’s actual pro-
blems will be identiﬁed and related to life story rela-
tions and components that inﬂuence this, for
example, cardiac arrest. The way in which assump-
tions and strategies established earlier in life have an
impact on the problem and on the negative thoughts
that are characteristic in relation to anxiety will be
investigated.
2. Psycho-education: This focuses on the dissemination
of information to the patient about the heart disease,
ICD and coping with everyday life. In relation to
anxiety, there will often be a need to help the patient
gain insight into the sympathetic nervous system’s
role in relation to development of anxiety and
increase knowledge of the association between
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negative automatic thoughts (catastrophic thoughts),
bodily intuitions, feelings and actions and how, for
example, behaviour experiments/exposure can
reduce anxiety in many situations.
3. Restructuring of negative automatic thoughts:
Preparation of a thought journal where the nurse
and patients analyse problematic situations by distin-
guishing ‘situation’, ‘physical feelings’, ‘feelings’,
‘automatic negative way of thinking’ and ‘behaviour’.
4. Planned behaviour experiments, consisting of
systematic exposure to situations that trigger the
anxiety.
5. Homework, for example, registration of the relation-
ship between thoughts, feelings and bodily sensa-
tions. These registrations form the foundation of
content in the following therapy: behaviour experi-
ments as practical training or exercises in
mastering.29
The intervention is considered ﬁnalised if the patient
has a HADS-A score under 8 after 2 consecutive consul-
tations or after 15 consultations.
Adherence is when the patient participates in all con-
sultations until HADS-A scores are below 8 for 2 con-
secutive weeks.
Figure 1 Flow chart.
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There are no restrictions on concomitant care in the
trial period.
Usual care
Both groups will receive usual care, which consists of
relevant medical therapy of the heart disease and stand-
ard follow-up of their ICD treatment according to
current guidelines. At one of the sites, patients are
invited to participate in a 2-hour patient education
meeting after ICD implantation, held every second
month.
Outcomes
Demographic variables and clinical characteristics will
be collected from patients and from patient records.
Data will be registered by trial staff when informed
consent is obtained.
Patient screening is performed by patients ﬁlling out
the self-reported HADS questionnaire.
Included patients will be interviewed with the aim of
determining the type of anxiety based on the Structured
Clinical Interview for DSM disorders (SCID-1).30 31
Patient-reported outcomes, investigator-evaluated out-
comes and objective outcomes are included.
The primary outcome of the RCT is anxiety measured
by HADS. HADS is a 14-item questionnaire that assesses
anxiety and depression level in medically ill persons who
are not admitted in psychiatric wards. The scale offers
two scores, HADS-A and HADS-D, and consists of seven
questions to assess anxiety and seven questions to assess
depression. HADS is a validated tool with Cronbach’s α
of 0.83 and 0.82. Scores of 0–7 for the two subscales are
regarded as normal and scores of 8–10 suggest the pres-
ence of a mood disorder. Scores of 11 and above suggest
the probable presence of a mood disorder.32
Secondary outcomes
Several secondary outcomes are planned.
Becks Anxiety Inventory (BAI): A self-reported
measure of anxiety with a focus on somatic symptoms of
anxiety. It was developed as a measure to discriminate
between anxiety and depression.33 The 21-item question-
naire assesses symptoms such as nervousness, dizziness
and fear of dying. The BAI score ranges from 0 to 63
and is interpreted as follows: 0–9, normal or no anxiety;
10–18, mild to moderate anxiety; 19–29, moderate to
severe anxiety; and 30–63, severe anxiety. The BAI has
been proved to be highly internally consistent with
Cronbach’s α of 0.94 and acceptably reliable over an
average time lapse of 11 days (r=0.67).34
The Hamilton Anxiety Scale (HAM-A): A clinical
interview rating scale of the psychic and somatic aspects
of anxiety. The scale consists of 14 clinical symptoms
that are rated on a 5-point Likert scale ranging from 0
(not present) to 4 (very severe).35 36 A manual for the
rating of symptoms is used. The score ranges from 0 to
56 and a score of 0–7 is interpreted as no anxiety dis-
order, 8–14 as questionable anxiety disorder, 15–19 as
mild anxiety disorder, 20–29 as moderate anxiety dis-
order and 30–56 as severe anxiety disorder. The reliabil-
ity and concurrent validity of the HAM-A has proved to
be sufﬁcient with an intraclass coefﬁcient of 0.74 and a
Spearman coefﬁcient of 0.63.37
HeartQoL: A disease-speciﬁc questionnaire that mea-
sures health-related quality of life in patients with heart
disease. The questionnaire consists of 14 items and pro-
vides two subscales: a 10-item physical subscale and a
4-item emotional subscale, which are scored from 0 to
3.38 The questionnaire has proven to be a reliable instru-
ment with Cronbach’s α between 0.80 and 0.91 for the
global score and each subscale and to be responsive in
patients with a wide spectrum of cardiac diagnoses.38–40
Exploratory outcomes
ICD shock, time to ﬁrst shock and antitachycardia
pacing (ATP) will be evaluated due to the risk of
arrhythmia stimulated by increased activation of the
autonomic nervous system. Data will be gathered from
the national ICD register that holds information on all
national ICD and cardiac resynchronisation therapy
device implantations. No difference is expected between
groups due to the small sample size. We will still explore
this outcome for the purpose of later meta-analyses and
data gathering for sample size estimation in future
trials.
Heart rate variability: Evo, Spacelab USA, is a portable
device for continuous monitoring of various electrical
variables of the cardiovascular system. Heart rate vari-
ability, blood pressure and heart rate are all responsive
to sympathetic activity, which can be increased by
anxiety. Heart rate variability refers to the beat-to-beat
variation in the RR interval and is a marker of auto-
nomic nervous system activity.41 Reduced heart rate vari-
ability is a powerful and independent predictor of
short-term and long-term mortality in cardiac
patients.42 43 Higher levels of anxiety are associated with
reduced heart rate variability.44 Owing to the small
sample size, this is not regarded as an outcome, but
rather data collection for future sample size calculations
in larger trials. Data will only be obtained in the inter-
vention group.
Ancillary questions
Questions about health-related lifestyle and their conse-
quences: sleep quality, physical activity, alcohol, smoking
and weight.
Demographic and clinical baseline information at inclusion
From patient record: Age, gender, heart disease and
comorbidity, ICD indication, type of ICD, prior VT/VF,
NYHA-classiﬁcation, ejection fraction, diabetes mellitus
and all medication.
Measurements: Heart rate variability (intervention
group only), weight, pulse, blood pressure.
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Demographic and clinical information after intervention
(at 16 weeks)
From questionnaire: All medication, other treatment for
anxiety in the project period, hospital admissions in the
project period.
Measurements: Heart rate variability (intervention
group only), weight, pulse, blood pressure.
Participant timeline
The timeline is presented in ﬁgure 2.
Sample size and power estimations
Sample size
A score below 8 on HADS-A is regarded as a normal
score. We wish to see a signiﬁcant difference between
the intervention and control groups to be sure that
development over time is not caused by a spontaneous
recovery but is an intervention effect.
An earlier study (n=334) showed that patients scoring
more than 8 on HADS-A had a mean score of 10.2 with
an SD of 2.3.1 If the patients with anxiety have a score
below 8, then the true difference between the interven-
tion and control groups should be 2.3 points.
With a power of 90% and a type 1 error set at 0.05, 22
patients should be entered in each group. There could
be a spontaneous improvement in the control group
and not all patients may beneﬁt from CBT.
Furthermore, we expect withdrawal from the study; this
is typically around 20–30% in similar intervention
studies. As a result, we double the inclusion uptake to
strengthen the trial, which means that we will need 44
intervention participants and 44 control participants
(88 participants in total).
Power estimations for secondary outcomes
BAI: In a previous study, the response within each par-
ticipant group was normally distributed with an SD of
5.45 If the true difference between the experimental and
control means is 5.2, we will be able to reject the null
hypothesis that the population means of the experimen-
tal and control groups are equal with a probability
(power) of 0.998.
HAM-A: Based on previous studies, the SD was set at
7.45–47 If the true difference in the experimental and
control means is 7, we will be able to reject the null
hypothesis that the population means of the experimen-
tal and control groups are equal with a probability
(power) of 0.996.
HeartQoL: In a previous study, the response within
each participant group was normally distributed with an
SD of 0.75.1 If the true difference in the experimental
and control means is 0.4, we will be able to reject the
null hypothesis that the population means of the experi-
mental and control groups are equal with a probability
(power) of 0.696.
Recruitment
All patients with ICD aged over 18 years who are admit-
ted to the hospital or at outpatient visit at one of the two
sites doing the time period of the trial are invited to ﬁll
out a questionnaire (HADS) screening for anxiety. By
screening patients at all types of hospital contacts,
patients with newly implanted ICDs and patients who
have had an ICD for many years will be included. In
patients who received a shock or were admitted to the
hospital, screening will take place 8 weeks after the event
to allow for normal restitution. The screening will con-
tinue until the target sample size is archived.
If a patient, after receiving verbal and written informa-
tion, decides to participate in the Screen-ICD trial, an
informed consent form will be signed and they will be
randomised to either: (1) a CBT intervention and usual
care or (2) usual care alone. The intervention is per-
formed by cardiac nurses with a certiﬁed cognitive
therapy education. The nurses are supervised by a
psychologist.
Allocation
Participants will be randomised 1:1 to the experimental
intervention group or to the control group.
Randomisation will be conducted using the web-based
tool Randomizer for Clinical Trials. The allocation
sequence will be computer-generated with a block size
of 4, concealed from the investigators. The allocation
will be conducted when the investigator calls a voice
respondent who logs in to ‘Randomizer for Clinical
Trials 1.8.1’, selects relevant participant information
(participant number and stratum) and assigns the
participant to either intervention or control by
phone to the investigator. The strata are severity of
anxiety measured by HADS-A (8–10 or 11–21) and age
(≤65 or >65 years).
Blinding
Owing to the conditions required for psycho-educational
interventions, it is not possible to blind the intervention
staff and patients. All baseline information and clinical
interviews are performed before randomisation. Data
management and administration will be performed by
blinded staff. Statistical analysis of outcomes and conclu-
sions from these will be blinded. Results of the trial are
analysed by an independent statistician, and the results
will be interpreted by the research group. The conclu-
sion will be prepared in two versions, before the alloca-
tion code is broken, with the two arms alternatively
assumed as intervention (one that assumes that arm A is
the intervention, and second, that assumes that the arm
B is intervention).
Data collection
The questionnaires for screening and collection of sec-
ondary outcomes are self-administered paper question-
naires handed out to the patient at the hospital or sent
to their home address.
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The SCID-1 and HAM-A interviews are performed by
ﬁve trained cardiac nurses. The ﬁrst three interviews are
performed by two nurses together to allow for training
and assure inter-rater concordance.
Trial participants are free to withdraw their informed
consent at any time and be treated according to the
department’s standard procedures. Patients who leave
the trial will be asked for permission to continue to
collect data and to use already collected data. If the
patient gives permission, data will be included in the
ﬁnal analysis.
Data management
Questionnaire responses will be typed and stored in a
secure folder with limited access on the hospital server.
The questionnaire data will be placed in one folder and
identiﬁed with a study participant number and in
another folder, the participant’s personal identiﬁcation
number will be stored with the matching study partici-
pant number.
Individual patient data will be handled as normal data
and records will be protected according to the Act on
Processing of Personal Data and the Danish Health Care
Figure 2 Participant timeline.
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Act. Data will be stored in accordance with Danish Data
Protection Agency rules. Anonymous data that are
encoded with the individual patient code will be entered
into the computerised database and transferred for ana-
lysis portal in encrypted mode. This system meets all cri-
teria for the handling of patient data in accordance with
the laws on the processing of personal data. All original
records are stored at Rigshospitalet for 15 years to allow
inspections by competent authorities. The trial database
will be preserved for 15 years and anonymised. After
analysis, experimental data will be submitted to the
Danish Data Archives.
Statistical analysis
The primary analyses will be performed according to the
intention-to-treat principle and we will use a mixed
model with repeated measurements for continuous out-
comes. For binary outcomes (HADS-A score <8), we use
a generalised mixed model with repeated measurements.
By using mixed models, we ensure that missing data do
not create bias as long as they are missing at random. In
the case of signiﬁcant results in the primary outcome,
sensitivity analyses will be performed to estimate the
potential effect of data missing at random by a worst-case
scenario. Let A be the group where a beneﬁcial signiﬁ-
cant effect is observed and B be the other group.
Missing values in group A will be imputed by the
minimum value found in the material and missing values
in group B will be imputed by the maximum value
found. The primary outcome will ﬁrst be tested using a
signiﬁcance level of 0.05. Analyses of the secondary
outcome measures as preplanned in the protocol will be
analysed with no adjustment of p values due to multipli-
city. Instead, the interpretation of each secondary
outcome measure will be assessed in the light of multiple
testing, that is, statistically signiﬁcant effects will be inter-
preted in the context of increased risk of type I error. No
signiﬁcance testing will be performed for the exploratory
outcomes. The clinical effect size is analysed by Cohen’s
d. Signiﬁcance level is set at 5%. SAS V.9.3 is used for the
analyses (SAS Institute, Cary, North Carolina, USA).
Data monitoring
Owing to the small sample size, no data monitoring
committee is established and no interim analyses will be
performed.
Harms
No risks are expected. CBT is a safe, non-invasive, non-
pharmacological treatment. There is a potential beneﬁ-
cial effect of participation in CBT as anxiety levels may
decrease.14 To avoid interference with normal restitu-
tion, an 8-week time span after an event must be upheld
before screening for anxiety. Adverse events will be con-
tinuously monitored.
Ethics
The trial is performed in accordance with the
Declaration of Helsinki in its latest form. All patients
must give informed consent to the investigators prior to
participation. All study- related information will be
stored securely at the study site. All informed consent
forms signed by participants will be stored in locked ﬁle
cabinets in areas with limited access. The trial is initiated
after approval by the Danish Data Protection Agency
(RH-2015-282) and the regional ethics committee
(H-16018868). The regional ethics committee will be
asked for permission in the case of protocol amend-
ments. The trial is registered at http://www.
ClinicalTrials.gov (NCT02713360). All investigators will
be given full access to the ﬁnal trial data set.
Dissemination
Positive, neutral and negative results of the trial will be
published. The ﬁnal manuscripts originating from the
trial will be sent to a peer-reviewed international journal.
Authorship will be allocated using the guidelines for
authorship set out by the International Committee of
Medical Journal Editors and will depend on the per-
sonal involvement of each author.
TRAJECTORY
The trial will begin in May 2016 with inclusion of the
ﬁrst participants. Inclusion will end when 88 patients are
enrolled in the RCT, expected to be by the end of 2016.
Data collection will end by mid-2017.
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